EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

EyePoint, Inc. ( EYPT ) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 8:00 AM EDT Company Participants Jay Duker - President, CEO & Director Ramiro Ribeiro - Chief Medical Officer George Elston - Executive VP & CFO Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Citigroup Inc., Research Division All right. So welcome, everyone, to Day 1 of Citi's Back-to-School Biopharma Conference here in New York City. Great to be back in New York. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. So our first session, it's my great pleasure to welcome the management of EyePoint Inc. We have Jay Duker, President and CEO; George Elston, EVP and CFO; and Ramiro Ribeiro, the CMO of the company. So welcome all of you. Thank you very, very much. Jay Duker President, CEO & Director Thanks for having us. Question & Answer Session Yigal Nochomovitz Citigroup Inc., Research Division Of course. So obviously, a lot has happened. You've had some Phase III data. You have another important -- very important Phase III result coming up soon in the fall. So Jay, maybe just to level set, if you could just introduce the company, introduce the goals of your lead program. And then I know we're going to have an important discussion about the LUGANO results and then what to expect, of course, for LUCIA in a few weeks. Jay Duker President, CEO & Director Sure. Thanks for the introduction, and thanks for the invitation. So at EyePoint, we are a company that specializes in drug delivery to the back of the eye. Our lead product is called DURAVYU. It is the vorolanib intravitreal insert. Vorolanib is a small molecule tyrosine kinase inhibitor, which has activity against all the VEGF receptors, PDGF, and JAK1, giving it an anti-inflammatory component.